Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $7.39
Previous CloseN/A
Volume226.18K
Average Volume (3M)3.26M
Market Cap
$618.77M
Enterprise Value$273.90M
Total Cash (Recent Filing)$32.40M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding96,682,230
10 Day Avg. Volume7,808,476
30 Day Avg. Volume3,256,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.23K
Enterprise Value/Ebitda-6.20
Forecast
1Y Price Target
$18.85Price Target Upside194.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe positive sample size re-estimation on CORAL and successfully completed abuse potential study are notable developments for TRVI.
Financial StabilityTrevi Therapeutics has a solid cash position of $107.6 million, providing financial stability until the second half of 2026.
Market PotentialThe recent RCC data was transformational for TRVI not only for the significant expansion of Haduvio's market potential but also due to evidence of efficacy at the lowest dose evaluated.
Bears Say
Financial NeedsTrevi does not have sufficient funds to complete the Phase 3 trial for IPF, indicating a need for additional financing in the future.
Market PerceptionTRVI shares could see some weakness based on the 'likeability' of clinical doses of nalbuphine ER being above the 11-pt margin vs placebo.
---
Ownership Overview
12.36% Insiders
5.94% Mutual Funds
55.61% Other Institutional Investors
18.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $2.30 and its highest was $7.39 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $618.77M.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Mar 18, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.018.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 96,682,230 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went up 3.811%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
---
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.85 (194.53% Upside)
$18.85 (194.53% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.27%
12-Months-Change
Fundamentals
Return on Equity
-52.59%
Trailing 12-Months
Asset Growth
24.04%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious neurological conditions. The company's lead product candidate, Haduvio, is being developed for the treatment of chronic pruritus (itch), and chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Trevi Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in these niche markets.
---
TRVI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical successes and a strong financial position, but increased losses and expenses present challenges. Overall, the positive clinical outcomes suggest a promising outlook for the company despite the financial setbacks.Read More>---
TRVI Stock 12 Month Forecast
Average Price Target
$18.85
▲(194.53% Upside)
Technical Analysis
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+77.95%
reiterated a buy rating 8 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +77.95% per trade.
---